Browse the evidence

Disruption of the circadian clock (via Clock or Bmal1 mutations) impairs lipid mobilization by reducing the rhythmic expression of lipolytic enzymes (Atgl and Hsl), leading to decreased free fatty acid release, increased adipose tissue accumulation, and fasting intolerance.

Your body's internal clock regulates how it releases fat for energy. Disrupting this clock (e.g., through irregular sleep, shift work, or erratic eating times) can blunt your body's ability to mobilize fat stores, potentially leading to increased fat accumulation and difficulty fasting. To support healthy lipid metabolism, prioritize consistent sleep-wake cycles and regular meal timing to align with your circadian rhythms.

Low socioeconomic position (proxied by low education) is independently associated with accelerated biological aging, as measured by epigenetic clocks (Horvath, Hannum, Levine) and stochastic epigenetic mutations (SEMs), with effect sizes comparable to major lifestyle risk factors like obesity and alcohol intake, though smoking has a stronger impact.

Your socioeconomic background, often measured by education level, has a measurable, independent impact on your biological aging speed, distinct from your daily habits. While you cannot change your past, this biological 'memory' is not entirely fixed; improving social conditions and managing lifestyle factors (especially avoiding smoking, which has the strongest epigenetic impact) can mitigate acceleration. Focus on controllable lifestyle levers, as they significantly influence epigenetic clocks.

DNA methylation levels at the CPT1A locus are inversely associated with BMI and waist circumference, suggesting that higher methylation leads to decreased gene expression and reduced adiposity.

This research highlights that your body's metabolic machinery (specifically fatty acid oxidation via CPT1A) is regulated by epigenetic switches. While you cannot directly 'dose' methylation, understanding that these switches exist supports the efficacy of lifestyle interventions (diet/exercise) which are known to alter methylation patterns. Focus on sustainable metabolic health rather than quick fixes.

Exogenous leptin administration during caloric restriction (dynamic weight loss) has minimal to no effect on body weight or energy expenditure in humans, primarily due to leptin resistance induced by negative energy balance.

Taking leptin while dieting will not help you lose weight and may increase hunger. The body's natural defense mechanisms (leptin resistance) block its effects during active weight loss. Focus on sustainable dietary changes rather than hormonal interventions for weight loss in non-deficient individuals.

Cool environmental temperatures (27–33 °C) directly activate a thermogenic gene program (including Ucp1 and Pgc1a) in white and beige adipocytes in a cell-autonomous manner, independent of the sympathetic nervous system and beta-adrenergic receptors.

This research suggests that your fat cells can directly sense cool temperatures and start burning energy, independent of your nervous system's stress response. While you don't need to freeze yourself, keeping your living environment slightly cooler (around 68-72°F or 20-22°C) may naturally support your body's ability to burn calories through this direct cellular mechanism, particularly in subcutaneous fat.

Thiazolidinediones (TZDs) increase circulating adiponectin levels, particularly the high molecular weight (HMW) form, by stimulating transcription and preventing ER retention.

This node describes a prescription medication class (TZDs) that increases adiponectin. This is not a self-administered intervention but a medical treatment for diabetes. Consult a physician for prescription options.

Low levels of adiponectin are associated with an increased risk of various cancers, including breast, liver, pancreatic, prostate, ovarian, and colorectal cancers.

Maintaining a healthy body weight helps preserve normal adiponectin levels, which may lower the risk of several obesity-associated cancers. This is one of many factors in cancer prevention.

Treatment with combined naltrexone-sustained release (32 mg) and bupropion-sustained release (360 mg) (NB32) attenuates hypothalamic brain reactivity to food cues while enhancing activation in regions responsible for self-control, memory, and interoception.

If you struggle with intense food cravings or lack of satiety signals, this medication (NB32) may help by reducing the brain's 'pull' towards food cues and enhancing your ability to use self-control and awareness of fullness. It is not a magic bullet but works by changing how your brain processes food signals. Consult a doctor to see if you are a candidate, as side effects can occur.

The decline in REM sleep associated with aging is primarily driven by elevated cortisol levels, whereas IL-6 levels do not significantly affect REM sleep in older adults.

For older adults, losing REM sleep is likely linked to higher cortisol levels, not necessarily inflammation (IL-6). This suggests that stress management techniques that lower cortisol might be more effective for preserving REM sleep than anti-inflammatory interventions alone.

Antioxidant supplementation does not increase maximum lifespan in vertebrates, whereas caloric restriction extends longevity by decreasing mitochondrial ROS production at complex I.

Do not rely on antioxidant supplements to extend your maximum lifespan. Instead, focus on interventions like caloric restriction, which have been shown to extend longevity by reducing mitochondrial ROS production at complex I.

PYY1-36 infusion does not significantly reduce energy intake in lean or obese subjects, although it may lower hunger ratings in lean individuals at low doses.

PYY1-36 infusions do not reduce food intake, even at higher doses. While it may slightly lower hunger feelings in lean people, it does not translate to eating less. It also increases heart rate and insulin response without the benefit of reduced calorie consumption, making it an ineffective strategy for weight management.

Satellite cells in aged human skeletal muscle remain intrinsically youthful and capable of robust regeneration, but fail to activate due to extrinsic niche factors (diminished MAPK/Notch signaling and elevated TGF-beta/pSmad3).

Aging muscle decline is largely due to the local environment suppressing stem cells, not the loss of the cells themselves. Therapies should focus on restoring the signaling environment (specifically MAPK/Notch pathways) to reactivate existing stem cells, rather than relying on stem cell transplantation.

Forced activation of the MAPK/Notch pathway restores youthful myogenic responses in satellite cells from 70-year-old humans.

Research suggests that targeting the MAPK/Notch signaling pathway could potentially reactivate dormant muscle stem cells in the elderly, offering a potential therapeutic avenue for age-related muscle loss.

Specific rare or low-frequency genetic variants (e.g., in SLC30A8, MTNR1B, PPARG) can have a large functional effect on T2DM risk, with some loss-of-function variants actually protecting against the disease.

While common genes have small effects, rare genetic mutations can drastically alter your diabetes risk. For example, certain mutations in the SLC30A8 gene actually protect against Type 2 Diabetes by improving insulin secretion. This highlights that genetics is complex and not all genetic changes are harmful; some can be protective and offer targets for new treatments.

Epigenetic modifications, particularly DNA methylation, serve as a mechanism through which environmental factors (such as intrauterine malnutrition, obesity, and diet) influence the development of Type 2 Diabetes.

Your environment directly impacts your genes through epigenetic changes like DNA methylation. Factors such as obesity, diet (e.g., palmitate exposure), and even prenatal nutrition can alter gene expression in ways that increase your risk for Type 2 Diabetes. This suggests that lifestyle interventions can potentially reverse or mitigate some of these epigenetic risks.

Shifting the sleep/wake schedule relative to the endogenous circadian rhythm (as seen in shift work) increases the daily peak-to-trough fluctuation of circulating leptin, resulting in lower leptin levels upon awakening.

If you work shifts or have an irregular sleep schedule, your body's internal clock may be out of sync with your sleep times, causing your leptin (satiety hormone) to drop significantly when you wake up. This low leptin state can increase appetite and food intake. To mitigate this, try to align your sleep schedule as closely as possible with your natural circadian rhythm, or use bright light exposure upon waking to help reset your internal clock.

Short-term surplus carbohydrate intake (50% excess for 5 days) significantly increases fasting hepatic glucose production (HGP) and serum insulin levels, creating a state of insulin resistance that suppresses lipolysis and shifts whole-body fuel selection toward carbohydrate oxidation and away from fat oxidation.

Eating significantly more carbohydrates than usual for a few days doesn't make you fat; it changes your metabolism to burn those carbs instead of fat. This happens because your liver produces more glucose and your insulin levels rise, which signals your body to stop breaking down fat stores. To manage this, be aware that high-carb meals will suppress fat burning for a period, regardless of total calories.

Fractional hepatic de novo lipogenesis (DNL) is a sensitive and specific biomarker for recent carbohydrate intake, increasing more than 10-fold on surplus carbohydrate diets and becoming unmeasurable on carbohydrate-deficient diets, even though absolute fat synthesis remains low.

While your body doesn't make much fat from carbs in the short term, the *rate* at which it attempts to do so changes dramatically based on how many carbs you eat. This metabolic signal can be used to estimate recent carb intake.

Obstructive Sleep Apnea (OSA) contributes to obesity through mechanisms including increased preference for calorie-dense foods, altered hormonal regulation (leptin resistance), and decreased physical activity due to daytime sleepiness.

If you have OSA, recognize that your sleep disorder may be driving your weight gain through hormonal changes and fatigue. Treating OSA (e.g., with CPAP) and exercising can help break the cycle of weight gain and improve sleep quality.

Pontine cholinergic neurotransmission is a causal factor in generating the activated brain state of REM sleep, including motor atonia.

This is a basic science finding. It explains the neurobiology of REM sleep but does not directly translate to a specific intervention for the general public.

Excessive mitochondrial ROS production in obesity drives insulin resistance by activating stress kinases like JNK and NF-κB, whereas controlled, low-level ROS signaling is required for normal insulin sensitivity and secretion.

In obesity, high levels of mitochondrial reactive oxygen species (ROS) contribute to insulin resistance by activating stress pathways like JNK. However, low levels of ROS are necessary for normal insulin function. Therefore, simply taking high-dose antioxidants to 'fight oxidative stress' may not be effective and could potentially interfere with necessary metabolic signaling. Focus on interventions that improve mitochondrial efficiency rather than just scavenging ROS.

Resting energy expenditure (REE) is determined primarily by the mass of metabolically active organs (brain, liver, heart, kidneys) rather than total fat-free mass or skeletal muscle, as organs constitute only ~5% of body weight but contribute 70-80% of REE.

Your resting calorie burn is driven mostly by your vital organs (liver, brain, heart, kidneys), not your skeletal muscle. While building muscle is healthy, it does not significantly increase your resting metabolic rate compared to the baseline cost of maintaining your organs. Accurate metabolic predictions require measuring organ mass, not just total body weight or muscle size.

The non-linear relationship between Resting Energy Expenditure (REE) and Fat-Free Mass (FFM) is explained by the changing proportion of metabolically active organ mass to skeletal muscle as body size increases.

If you are larger, your resting metabolism per pound of lean tissue is lower than that of a smaller person. This is because your vital organs, which burn the most energy, make up a smaller fraction of your total body weight. Simple linear formulas often overestimate the metabolic cost of large amounts of skeletal muscle.

Resting Energy Expenditure can be accurately reconstructed from detailed body composition analysis using MRI or CT-derived organ masses multiplied by constant organ tissue-respiration rates.

For young, healthy adults, you can accurately predict your resting metabolism if you know your exact organ masses (via MRI/CT). However, this is currently impractical for most people. For general use, knowing your trunk lean mass is a better predictor than total body weight or simple muscle mass.